$SNDK Sandisk's previously announced 8-for-1 forward stock split took effect following Thursday's market close, with eligible shareholders receiving seven additional shares for each share they owned.
100
The S&P 500 is falling about 2% and the Nasdaq Composite (^IXIC) about 3.5%, enough to wipe out the Nasdaq's gain for 2026.
93
$ANVS FDA agrees with plan to pool safety data from four Alzheimer's and Parkinson's studies and to integrate it at the level of standardized analysis datasets
Safety package will be built in parallel with ongoing studies; NDA submission planned after DUET-AD data readout
95
$SVRA The review of the BLA is ongoing and no revised action date has been provided by the agency.
131
$SVRA the US Food and Drug Administration communicated that it will not meet the target action date of the company's biologics license application for molgramostim inhalation solution, which is intended for autoimmune pulmonary alveolar proteinosis, a rare lung disorder.
141
$BLTE said the US Food and Drug Administration has extended its review of the marketing application for its experimental drug tinlarebant, which is being developed to treat Stargardt disease type 1, by three months
98
$SLS Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 1,730,769 additional shares of Common Stock on the same terms as the Offering Shares
The Company expects to receive net proceeds from the offering of approximately $161.8M
2
286
$NXAT because the Company effected a 1-for-30 reverse stock split on August 3, 2026, it is not eligible for the customary 180-calendar-day compliance period
217
Wells Fargo $WFC stood out among the 19 wirehouses and brokerage platforms Galaxy tracks. Its holdings rose by 14,636 BTC to 30,553, nearly doubling from 15,931 at the end of June.
128
Artificial intelligence has sped up early-stage drug development work at some of the world's largest pharmaceutical companies this year, cutting by as much as half the time it takes to produce new molecules and move them into the clinic
110
Markets are pricing in a 98.4% chance of an interest rate hike from the central bank at its next meeting in December 2026
117
Tango Therapeutics $TNGX plans to disclose lung cancer data for vopimetostat in January 2027.
187
Crescent Biopharma $CBIO expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in the first quarter of 2027
139
Cullinan Therapeutics $CGEM and partner Taiho Oncology are awaiting an FDA decision on zipalertinib, with a target action date of February 27, 2027.
153
$ANNX ARCHER II completion, including Month 24 analyses, is expected in the third quarter of 2027.
If the DMC recommends that the endpoint has been met, the DMC will evaluate the two pre-specified sub-studies, with results anticipated in the first quarter of 2027.
222
$ANNX Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026;
Tanruprubart EU MAA Currently Under Review
An independent Data Monitoring Committee will assess the ARCHER II single study Month 15 primary endpoint in 4thQ2026
197
